New Hope on the Horizon - Advances in the Diagnosis and Treatment of Idiopathic Hypersomnia is organized by Healio.
Release Date: November 21, 2023
Expiration Date: November 21, 2024
Activity Description:
Idiopathic hypersomnia (IH) is a chronic neurological disorder that has significant impacts on daily functioning, with symptoms that include, but often go beyond excessive daytime sleepiness (EDS). Overall awareness about IH remains low, which contributes to the suboptimal recognition of this condition, which is often exacerbated by insufficient diagnostic criteria leading to delayed diagnosis and treatment. Until recently, there was no FDA-approved treatment option for IH, and historically, although IH is not the same as narcolepsy, the same treatment options were offered, leading to suboptimal treatment response and exacerbation of disease burden. Recent advances, with a new option now approved and other agents in development, can help close some of the current gaps.
In this activity, experts will offer expert perspectives on the impact of IH, as well as best practices and advances for its screening, diagnosis, and treatment. The information is presented in an easy and digestible format, accompanied by additional resources and suggested readings.
Learning Objectives:
After completing this activity, the participant should be better able to:
• Review the pathophysiology, definitions, and the burden of idiopathic hypersomnia (IH) on patients’ quality of life.
• Summarize the clinical features and the current and emerging diagnostic parameters for IH.
• Discuss the burden of IH and practical approaches to assess the severity of IH symptoms.
• Describe conventional treatment options for IH and challenges with current treatments.
• Outline the rationale, efficacy, and safety of new and emerging therapies for the treatment of IH.